Terragen Holdings Ltd · ASX:TGH
Terragen — Investor Presentation (August 2023)
12 slides from Terragen's investor presentation, Aug 3, 2023
Slide 1: Terragen FY23 Q4 investor presentation (ASX announcement)
For immediate release 3 August 2023 ASX Announcement Terragen FY23 Q4 investor presentation Terragen Holdings Limited (ASX:TGH) is holding a series of investor presentations following on from the recent release of the FY23 Q4 quarterly update. A copy of the presentation materials is attached. For pe
Slide 2: Investor Briefing - FY23 Q4
Terragen Holdings Limited For personal use only ASX: TGH Investor Briefing - FY23 Q4
Slide 3: Disclaimer for ASX Release
DISCLAIMER FOR ASX RELEASE For personal use only This presentation (Presentation) has been prepared by Terragen Holdings Limited (Terragen) for its Future performance - This Presentation contains forward looking statements which, in some instances ASX Release. may be identified by terminology such a
Slide 4: Introduction to Terragen
Introduction to Terragen (ASX:TGH) For personal use only Terragen develops microbial biological solutions to address animal and soil health, productivity and methane reduction Overview Key Products • Biological products for agriculture, both in the soil health and animal health and nutrition sectors
Slide 5: FY23 Q4 Executive Summary
For personal use only FY23 Q4 Executive Summary • Capital Raise Process ongoing, General Meeting expected on or about 4th September 2023. • Scientific programme continues, as Terragen invests in projects with the potential to driving a material difference to its market offering. • Studies show posit
Slide 6: Study/trial results continue to support the business case for MYLO
Study/trial results continue to support the For personal use only business case for MYLO® • MYLO is a direct fed microbial supplement, proven to help improve calf and cattle health and productivity, thereby elevating financial returns for farmers. • Harrisville, QLD study shows that cows on MYLO had
Slide 7: Allocating resource to research supporting biologicals in agriculture
Terragen allocating resource to research which supports For personal use only the use of biologicals in key agricultural activities • Terragen has produced small scale “dry MYLO” for use as a dry form feed supplement in an ongoing study by the University of Queensland. o Analysis of data is ongoing,
Slide 8: LACTOLIN teat wash in early stage development
For personal use only LACTOLIN teat wash in early stage development • LACTOLIN is an alternative offering to teat washes that are based on harsh chemicals (iodine or chlorhexidine) • As a universal dairy activity, the global market for teat washes is substantial. • A previous study has shown great p
Slide 9: Exploring options for increasing use of GREAT LAND PLUS
Terragen continues to explore options for increasing use For personal use only of GREAT LAND PLUS® • GREAT LAND PLUS is a patented chemical free soil conditioner, containing live, naturally occurring bacteria that boosts soil health and crop yields. It was developed as an effective alternative to ch
Slide 10: FY23 financial performance has stabilised, sales recovered, costs reduced
Terragen’s FY23 financial performance has For personal use only stabilised, sales recovered, costs reduced1 • FY23 total net revenue of $2.47m, up 12.1% vs prior year, driven by a smaller, more focussed sales team. o MYLO sales of $1.89m, up 10% vs prior year. o GREAT LAND PLUS sales of $0.58m, up 1
Slide 11: In summary
For personal use only In summary: 1. Recent studies validate the continued investment of capital into purposeful research and development. 2. MYLO’s business case for farmers is reinforced by study results in both dairy and beef segments. 3. The financial base of the business is improving, allowing
Slide 12: For personal use only
@p Terragen Ajuo asn jeuosied JOS
Terragen Holdings — Investor Presentation (August 2023) on 6ix